Healwell AI (AIDX.TO TSX) C$0.81 +5.19% 02 Apr 2026: AI gains, cash risks

The AIDX.TO stock closed at C$0.81, up 5.19% on 02 Apr 2026 as volume reached 995,869 shares on the TSX. Healwell AI Inc. (AIDX.TO) is trading below its 200-day average of C$1.13, reflecting investor caution despite AI-driven product positioning. The move came in a market-closed session, and the stock’s short-term momentum contrasts with negative earnings metrics. Investors focused on AI stocks should weigh Healwell AI’s platform growth against tight liquidity and a negative EPS of -0.15.

AIDX.TO stock market snapshot

Healwell AI (AIDX.TO) closed at C$0.81, a C$0.04 gain or +5.19% on 02 Apr 2026. The session high was C$0.86 and low C$0.78, with 995,869 shares traded versus average volume 520,140. Market capitalization stands at C$237.59M and shares outstanding are 293,322,517, all on the TSX in Canada.

AIDX.TO stock valuation and financials

Healwell AI reports EPS of -0.15 and a trailing PE of -5.40, reflecting current losses. Price-to-sales is 2.05 and price-to-book is 1.92, while the current ratio is 0.91, indicating near-term liquidity pressure. The company’s net margin is -40.12% and revenue per share is 0.40, which shows revenue base but weak profitability.

AIDX.TO stock AI strategy and growth

Healwell AI focuses on AI-enabled decision support for preventative care and holds a strategic alliance with WELL Health Technologies. The company spent 14.17% of revenue on R&D, underscoring the AI development emphasis. Recent growth trends show revenue growth of 4.33% year over year, but free cash flow per share is negative at -0.07.

AIDX.TO stock technicals and trading

Technically, the AIDX.TO stock sits near its 50-day average C$0.79 and below the 200-day average C$1.13, with RSI at 49.76, implying neutral momentum. Bollinger Bands range C$0.72–C$0.99, and on-balance volume is 28,812, suggesting modest accumulation. Short-term traders should note the relative volume of 1.91, which shows above-average intraday interest.

AIDX.TO stock Meyka grade and model forecast

Meyka AI rates AIDX.TO with a score out of 100: 57.75 (C+) — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a short-term target of C$0.72 and a monthly view of C$0.65. Compared with the current C$0.81, the C$0.72 projection implies -11.11% downside while C$0.65 implies -19.75%. Forecasts are model-based projections and not guarantees.

AIDX.TO stock risks and sector context

Healwell AI operates in the Healthcare sector where average metrics show higher stability than Healwell’s current ratios. Key risks include tight liquidity, negative operating cash flow per share -0.07, and debt-to-equity of 0.69. On the opportunity side, AI adoption in preventative care and the WELL Health tie-up could lift revenue if product uptake scales.

Final Thoughts

AIDX.TO stock closed at C$0.81 on 02 Apr 2026 after a +5.19% session, but underlying metrics show mixed signals. Meyka AI assigns a C+ (57.75) grade and models a near-term target of C$0.72, implying roughly -11.11% from today’s price; a conservative monthly projection is C$0.65. Positive points include a focused AI healthcare strategy, 14.17% R&D intensity, and an alliance with WELL Health. Headwinds include negative EPS (-0.15), sub-1.0 current ratio, negative free cash flow per share (-0.07) and heavier debt relative to equity. For investors in AI stocks, AIDX.TO offers thematic exposure but requires close monitoring of cash flow, execution on product commercialization, and upcoming earnings on 13 May 2026. These forecasts are model-based projections and not guarantees. Meyka AI, an AI-powered market analysis platform, highlights that AIDX.TO is a speculative AI healthcare pick best suited for investors willing to accept execution and liquidity risk while tracking short-term technical levels and company updates.

FAQs

What drove today’s move in AIDX.TO stock?

The AIDX.TO stock rise to C$0.81 was driven by above-average volume and short-term buying interest. No major company press release was issued; the move reflects sector rotation into AI healthcare and intraday momentum.

How does Meyka AI rate AIDX.TO stock?

Meyka AI rates AIDX.TO with a score out of 100: 57.75 (C+) — HOLD. The grade weighs benchmark and sector comparisons, financial growth, key metrics, and forecasts. This is informational and not investment advice.

What is the short-term price outlook for AIDX.TO stock?

Meyka AI’s forecast model projects a short-term target of C$0.72 and a monthly view of C$0.65. Compared with C$0.81, those figures imply downside in the near term. Forecasts are not guarantees.

What are the main risks for AIDX.TO stock investors?

Key risks include negative EPS (-0.15), negative free cash flow per share (-0.07), a current ratio below 1.0, and execution risk in commercializing AI products. Debt-to-equity is 0.69, adding leverage considerations.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.